Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene

Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene

Source: 
Pharmaceutical Business Review
snippet: 


Bristol-Myers Squibb (BMS) has completed the acquisition of US-based biotechnology company Celgene in a cash-cum-stock deal worth around $74bn.